NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
77.00 -0.57 (-0.73%) GOLD FUTURES
2,348.10 -44.80 (-1.87%) DOW
39,397.83 -273.21 (-0.69%) Bitcoin GBP
53,415.52 -2,097.58 (-3.78%)
AUPH Jul 2024 6.000 call
| Previous close | 0.3200 |
| Open | 0.3000 |
| Bid | 0.1000 |
| Ask | 0.3000 |
| Strike | 6.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.3000 - 0.3200 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.51k |
Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.
Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 09, 2024--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ZacksHow Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
